Terlipressin Improves Renal Function and Reverses Hepatorenal Syndrome in Patients With Systemic Inflammatory Response Syndrome

• Published in: Clinical gastroenterology and hepatology Vol. 15; no. 2; pp. 266 - 272.e1
• Main Authors: Wong, Florence, Pappas, Stephen Chris, Boyer, Thomas D., Sanyal, Arun J., Bajaj, Jasmohan S., Escalante, Shannon, Jamil, Khurram
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.02.2017
• Subjects: Aged; Canada; Cirrhosis; Female; Gastroenterology and Hepatology; Hepatorenal Syndrome - complications; Hepatorenal Syndrome - drug therapy; HRS-1; Humans; Lypressin - analogs & derivatives; Lypressin - therapeutic use; Male; Middle Aged; Placebos - administration & dosage; Renal Dysfunction; Retrospective Studies; REVERSE Trial; Survival Analysis; Systemic Inflammatory Response Syndrome - complications; Systemic Inflammatory Response Syndrome - drug therapy; Treatment Outcome; United States; Vasoconstrictor Agents - therapeutic use; HRS-1; Cirrhosis; SD; SIRS; SCr; Renal Dysfunction; REVERSE Trial; CHRSR; serum creatinine; systemic inflammatory response syndrome; complete hepatorenal syndrome reversal; hepatorenal syndrome type 1; standard deviation
• ISSN: 1542-3565; 1542-7714; 1542-7714
• DOI: 10.1016/j.cgh.2016.07.016

Patients with systemic inflammatory response syndrome (SIRS) along with decompensated cirrhosis and renal dysfunction have a poor prognosis and a lower response to treatment. We evaluated the effect of SIRS on the response of hepatorenal syndrome type 1 (HRS-1) to terlipressin. We performed a retrospective study of data from a trial of the effects of terlipressin (1 mg every 6 hours or placebo with concomitant albumin) in 198 patients with HRS-1, performed at 50 investigational sites in the United States and 2 in Canada from October 2010 through February 2013. We identified patients with 2 or more criteria for SIRS, without untreated infections (28 received terlipressin and 30 received placebo), and patients with less than 2 criteria for SIRS (control subjects). Primary endpoints included HRS reversal (a decrease in serum level of creatinine to ≤1.5 mg/dL), confirmed HRS reversal (defined as 2 serum creatinine levels ≤1.5 mg/dL, ≥ 48 hours apart), and survival for 90 days after treatment. Baseline characteristics were similar between groups, apart from slightly higher white blood cell counts and heart rates, and slightly lower serum levels of bicarbonate in patients with SIRS versus without SIRS. HRS was reversed in 42.9% of patients who received terlipressin with SIRS (12/28) versus 6.7% of patients who received placebo (2/30) (P = .0018); confirmed HRS reversal occurred in 32.1% of patients who received terlipressin with SIRS (9/28) versus 3.3% who received placebo (1/30) (P = .0048). A larger proportion of patients with SIRS who received terlipressin survived for 90 days without a transplant (13/28; 46.4%) than patients with SIRS who received placebo (7/30; 23.3%) (P = .076). In an analysis of data from a placebo-controlled study, we found that terlipressin improved renal function and reversed HRS in a higher proportion of patients with HRS-1 and SIRS than patients who received albumin plus placebo. ClincialTrials.gov, number NCT 01143246.